Publications en collaboration avec des chercheurs de Maastricht University Medical Centre (10)

2020

  1. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial

    Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654

  2. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial

    Osteoporosis International, Vol. 31, Núm. 10, pp. 1935-1942

  3. Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use"

    Journal of Clinical Endocrinology and Metabolism

  4. Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling

    Biological Psychiatry, Vol. 87, Núm. 2, pp. 100-112

  5. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Bone, Vol. 130

2019

  1. Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita

    Human Mutation, Vol. 40, Núm. 12, pp. 2270-2285

  2. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Archives of Osteoporosis, Vol. 14, Núm. 1

2018

  1. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

    Journal of Bone and Mineral Research, Vol. 33, Núm. 5, pp. 783-794

  2. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

    The Lancet, Vol. 391, Núm. 10117, pp. 230-240

  3. Teriparatide vs risedronate for osteoporosis – Authors' reply

    The Lancet